SCHEMBL6237560

SCHEMBL6237560

O=C(O)CC1=Nc2ccccc2S(=O)(=O)N1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.39
CA2 P00918 5/20 0.39
CA9 Q16790 5/20 0.39
CA1 P00915 4/20 0.39
CA4 P22748 4/20 0.39
CA7 P43166 4/20 0.39
KDM4E B2RXH2 1/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
BCHE P06276 1/20 0.39
CA6 P23280 1/20 0.39
CA5A P35218 1/20 0.39
KMT2A Q03164 1/20 0.39
CA14 Q9ULX7 1/20 0.39
CA5B Q9Y2D0 1/20 0.39
HTT P42858 1/20 0.37
AKR1B1 P15121 2/20 0.36
ALDH1A1 P00352 2/20 0.34
HSD11B1 P28845 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6235954 0.81 CA2 (0.40) CA12CA2CA9CA1CA4
SCHEMBL5782636 0.80 HSD17B10 (0.41) CA12CA2CA9KDM4EUSP2
SCHEMBL6237565 0.80 CA2 (0.31) CA12CA2CA9CA1CA4
SCHEMBL8447152 0.79 KMT2A (0.38) CA12CA2CA9CA1CA4
SCHEMBL28591321 0.76 CA12 (0.39) CA12CA2CA9CA1CA4
SCHEMBL11339126 0.76 CA9 (0.40) CA12CA2CA9CA1CA4
SCHEMBL6431070 0.76 CA12 (0.42) CA12CA2CA9CA1CA4
SCHEMBL28596138 0.74 ALPL (0.37) CA12CA2CA9CA1CA4
SCHEMBL20773595 0.71 CA12 (0.41) CA12CA2CA9CA1CA4
SCHEMBL20777648 0.71 CA12 (0.41) CA12CA2CA9CA1CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP disclosed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US disclosed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP disclosed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 CA12 4222/4885CA2 4750/4885CA9 4375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.